
Eli Lilly $3.8B Vaccine Acquisitions: Infectious Disease R&D
Examine Eli Lilly's $3.8B acquisition of three biotechs to build an infectious disease vaccine pipeline targeting shingles, EBV, and resistant bacteria.
IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.

Examine Eli Lilly's $3.8B acquisition of three biotechs to build an infectious disease vaccine pipeline targeting shingles, EBV, and resistant bacteria.
© 2026 IntuitionLabs. All rights reserved.